PHI and leading supplier of cell analysis instrumentation sign agreement
Phase Holographic Imaging (PHI) and a major publicly traded international supplier of laboratory equipment and cell analysis instrumentation have entered an agreement aiming to determine the scope and nature of a future partnership. The agreement is a result of discussions between the company management teams, over an extended period time.
The discussions found that there is a mutual interest to realize the full market potential of PHI’s HoloMonitor cell analysis technology by providing the technology with substantial resources, particularly within sales and marketing. It was further concluded that PHI's visionary technical capabilities superbly complement the instrument supplier's sophisticated scientific marketing.
Unrelated to the above and as previously communicated, PHI and a leading US-based manufacturer of reagents and antibodies entered a technology assessment agreement in February 2019, primarily focused on immuno-oncology applications. After a successful evaluation, negotiations regarding a scientific cooperation have been initiated, as a second step to create the basis for future business negotiations between the companies.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 21, 2019.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.